Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?

ABSTRACT:

Background

To evaluate if early improvements in pain and function with subcutaneous tanezumab are meaningful and sustained over 24 weeks.

Methods

Patients with moderate-to-severe osteoarthritis (hip or knee) in Europe and Japan were randomized to placebo, tanezumab 2.5 mg or tanezumab 5 mg (baseline, Week 8 and Week 16). Outcomes included: average daily index joint pain score, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) subscales, rescue medication use, WOMAC responders (within-patient ≥30% reduction in WOMAC Pain or Physical Function), Outcome Measures in Rheumatology-Osteoarthritis Research Society International (OMERACT-OARSI) responders (within-patient) and Patient-reported Treatment Impact Assessment-Modified questionnaire.

Results

Pati

SUBMITTER: Berenbaum F 

PROVIDER: S-EPMC8360021 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature